QPPV.COM KNOWLEDGE ASSESSMENT

Trazodone: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Trazodone: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best distinguishes a recommended internal pharmacovigilance practice from a universal statutory requirement?
Question 2 of 10 How should the American Academy of Sleep Medicine's weak recommendation against trazodone for chronic insomnia be understood?
Question 3 of 10 A patient is switched from immediate-release tablets to an extended-release product containing the same active ingredient. What is the key safety consideration?
Question 4 of 10 What is the most accurate interpretation of the US approval of Raldesy oral solution for major depressive disorder?
Question 5 of 10 A caregiver is using Raldesy oral solution labelled at 10 mg/mL. Which follow-up information is most useful if an overdose or underdose is suspected?
Question 6 of 10 An older adult taking a thiazide develops confusion and severe hyponatraemia soon after starting trazodone. What is the most appropriate causality approach?
Question 7 of 10 Why are spontaneous-report counts alone inadequate for estimating the incidence of trazodone-associated falls or arrhythmias?
Question 8 of 10 Why should secondary sleep or anxiety findings from a depression trial be interpreted cautiously when multiple outcomes were assessed?
Question 9 of 10 A young adult develops suicidal thoughts after starting trazodone. Which case assessment best supports balanced interpretation?
Question 10 of 10 Which approach is most useful when reviewing a potential safety signal for a widely used generic medicine such as trazodone?

Select an answer to continue.

QPPV.com